Clinical Trial

CONVERGE Post-Approval Study (PAS)

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-05-24; most recent amendment 2026-04-21.
Status change: Recruiting → Active, Not Recruiting 2025-10-16
Trial Details
NCT Number NCT05393180
Lead Sponsor AtriCure, Inc.
Conditions Chronic Atrial Fibrillation
Enrollment 53 participants
Start Date 2022-04-13
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-22